ponsegromab
{{Short description|Monoclonal antibody}}
{{Orphan|date=December 2023}}
{{Infobox drug
| type = mab
| image =
| alt =
| caption =
| synonyms = PF-06946860
| mab_type =
| source =
| target = GDF-15
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration =
| ATC_prefix =
| ATC_suffix =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US =
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status = Investigational
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =
| CAS_number = 2368950-15-4
| PubChem =
| UNII = GXA6PF0254
| DrugBank =
| KEGG =
}}
Ponsegromab (PF-06946860) is a monoclonal antibody that works as a GDF-15 inhibitor. It is developed by Pfizer for cancer cachexia.{{cite journal |last1=Nishie |first1=Kenichi |last2=Nishie |first2=Tomomi |last3=Sato |first3=Seiichi |last4=Hanaoka |first4=Masayuki |title=Update on the treatment of cancer cachexia |journal=Drug Discovery Today |date=September 2023 |volume=28 |issue=9 |pages=103689 |doi=10.1016/j.drudis.2023.103689|pmid=37385369 |s2cid=259294809 }}{{cite journal |last1=Roeland |first1=E.J. |last2=Yennu |first2=S. |last3=Del Fabbro |first3=E. |last4=Buckeridge |first4=C. |last5=Thayer |first5=K.M. |last6=Collins |first6=S.M. |last7=Lubaczewski |first7=S.L. |last8=Wang |first8=E.Q. |last9=Calle |first9=R.A. |title=1696TiP Phase Ib study to assess the effect of PF-06946860 on appetite following subcutaneous administration in patients with anorexia and advanced cancer |journal=Annals of Oncology |date=September 2021 |volume=32 |pages=S1185 |doi=10.1016/j.annonc.2021.08.1668|doi-access=free }}{{cite journal |last1=Crawford |first1=Jeffrey |last2=Lubaczewski |first2=Shannon L |last3=Tarachandani |first3=Anil |last4=Harrington |first4=Magdalena A |last5=Weng |first5=Yan |last6=Qiu |first6=Ruolun |last7=Collins |first7=Susie M |last8=Rossulek |first8=Michelle I |last9=Revkin |first9=James H |title=Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia. |journal=Journal of Clinical Oncology |date=1 June 2023 |volume=41 |issue=16_suppl |pages=TPS12147 |doi=10.1200/JCO.2023.41.16_suppl.TPS12147}}{{cite journal |last1=Crawford |first1=Jeffrey |last2=Calle |first2=Roberto A. |last3=Collins |first3=Susie M. |last4=Weng |first4=Yan |last5=Lubaczewski |first5=Shannon L. |last6=Buckeridge |first6=Clare |last7=Wang |first7=Ellen Q. |last8=Harrington |first8=Magdalena A. |last9=Tarachandani |first9=Anil |last10=Rossulek |first10=Michelle I. |last11=Revkin |first11=James H. |title=Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy |journal=Cancer Research |date=14 April 2023 |volume=83 |issue=8_Supplement |pages=CT108 |doi=10.1158/1538-7445.AM2023-CT108|s2cid=258165004 }}{{cite journal |last1=Talbert |first1=Erin E. |last2=Guttridge |first2=Denis C. |title=Emerging signaling mediators in the anorexia–cachexia syndrome of cancer |journal=Trends in Cancer |date=May 2022 |volume=8 |issue=5 |pages=397–403 |doi=10.1016/j.trecan.2022.01.004|doi-access=free |pmid=35190301 |pmc=9035074 }}
In September 2024, Pfizer disclosed that ponsegromab led to significant body weight increases in patients with non-small cell lung cancer, pancreatic cancer, or colorectal cancer in a phase 2 clinical trial.{{Cite web |title=Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia {{!}} Pfizer |url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer-presents-positive-data-phase-2-study-ponsegromab |access-date=2024-10-28 |website=www.pfizer.com |language=en}}